Most pediatric ALCL cases carry ALK gene fusions (ALK-positive ALCL) that constitutively activate RAS-ERK, JAK3-STAT3 and PI3K–Akt oncogenic signaling pathways, thus promoting cancer cell proliferation, differentiation, and survival (1). This evidence concerns the gene AKT1 and anaplastic large cell lymphoma.